The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca
Executive Summary
Amidst excitement over the potential of PD-1/PARP inhibitor combos in multiple tumor types, Clovis signs a non-exclusive agreement to test Rubraca with Bristol's Opdivo in ovarian, breast and prostate cancer.
You may also be interested in...
Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Ovarian Cancer Pipeline Review: Sponsors Plan Frontline Punch, Smart Combinations
Combination studies of drugs for ovarian cancer have heavy focus on PARP, PD-1/L1 and VEGF mechanisms.
How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value
With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.